These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 18091578)

  • 1. The impact of acute myocardial ischemia on the ventricular defibrillation threshold during chronic oral azimilide therapy.
    Chevalier P; Dubieff AD; Piqueras E; Pineau J; Rivard L; Morel E; Bui-Xan B; Timour Q
    J Cardiovasc Pharmacol; 2007 Dec; 50(6):629-32. PubMed ID: 18091578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic oral amiodarone but not dronedarone therapy increases ventricular defibrillation threshold during acute myocardial ischemia in a closed-chest animal model.
    Chevalier P; Timour Q; Morel E; Bui-Xuan B
    J Cardiovasc Pharmacol; 2012 Jun; 59(6):523-8. PubMed ID: 22330675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation.
    Qi XQ; Newman D; Dorian P
    J Interv Card Electrophysiol; 1999 Mar; 3(1):61-7. PubMed ID: 10354978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of transient myocardial ischemia on the ventricular defibrillation threshold.
    Anastasiou-Nana MI; Tsagalou EP; Charitos C; Siafakas KX; Drakos S; Terrovitis JV; Ntalianis A; Doufas A; Mavrikakis J; Nanas JN
    Pacing Clin Electrophysiol; 2005 Feb; 28(2):97-101. PubMed ID: 15679638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biphasic waveform external defibrillation thresholds for spontaneous ventricular fibrillation secondary to acute ischemia.
    Walcott GP; Killingsworth CR; Smith WM; Ideker RE
    J Am Coll Cardiol; 2002 Jan; 39(2):359-65. PubMed ID: 11788232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of ventricular fibrillation duration and site of initiation on the defibrillation threshold during early ventricular fibrillation.
    Strobel JS; Kenknight BH; Rollins DL; Smith WM; Ideker RE
    J Am Coll Cardiol; 1998 Aug; 32(2):521-7. PubMed ID: 9708486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The shocking story of azimilide.
    Hanna IR; Langberg JJ
    Circulation; 2004 Dec; 110(24):3624-6. PubMed ID: 15596558
    [No Abstract]   [Full Text] [Related]  

  • 8. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database.
    Pratt CM; Al-Khalidi HR; Brum JM; Holroyde MJ; Schwartz PJ; Marcello SR; Borggrefe M; Dorian P; Camm AJ;
    J Am Coll Cardiol; 2006 Aug; 48(3):471-7. PubMed ID: 16875971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.
    Dorian P; Borggrefe M; Al-Khalidi HR; Hohnloser SH; Brum JM; Tatla DS; Brachmann J; Myerburg RJ; Cannom DS; van der Laan M; Holroyde MJ; Singer I; Pratt CM;
    Circulation; 2004 Dec; 110(24):3646-54. PubMed ID: 15533855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators.
    Singer I; Al-Khalidi H; Niazi I; Tchou P; Simmons T; Henthorn R; Holroyde M; Brum J
    J Am Coll Cardiol; 2004 Jan; 43(1):39-43. PubMed ID: 14715180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of azimilide, a new class III antiarrhythmic drug, on reentrant circuits causing ventricular tachycardia and fibrillation in a canine model of myocardial infarction.
    Schmitt H; Cabo C; Coromilas JC; Wit AL
    J Cardiovasc Electrophysiol; 2001 Sep; 12(9):1025-33. PubMed ID: 11573692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of isoproterenol on the class III effect of azimilide in humans.
    Dorian P; Dunnmon P; Elstun L; Newman D
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):211-7. PubMed ID: 12490966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of myocardial ischemia and reperfusion on ventricular defibrillation patterns, energy requirements, and detection of recovery.
    Qin H; Walcott GP; Killingsworth CR; Rollins DL; Smith WM; Ideker RE
    Circulation; 2002 May; 105(21):2537-42. PubMed ID: 12034662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator.
    Kaźmierczak J; Peregud-Pogorzelska M; Rzeuski R
    Pacing Clin Electrophysiol; 2007 Aug; 30(8):1043-6. PubMed ID: 17669094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of the SHock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator.
    Pratt CM; Dorian P; Al-Khalidi HR; Brum JM; Borggrefe M; Tatla DS; Brachmann J; Myerburg RJ; Cannom DS; Holroyde MJ; van der Laan M; Hohnloser SH;
    Am J Cardiol; 2005 Jan; 95(2):274-6. PubMed ID: 15642569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia.
    Brooks RR; Carpenter JF; Miller KE; Maynard AE
    Proc Soc Exp Biol Med; 1996 May; 212(1):84-93. PubMed ID: 8618956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiological effects of azimilide in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium.
    Ducroq J; Rouet R; Puddu PE; Sallé L; Tabourel C; Ducouret P; Gérard JL
    Eur J Pharmacol; 2005 Aug; 518(2-3):165-74. PubMed ID: 16083874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation.
    Pritchett EL; Schulte MC; Schnell D; Marcello SR; Wilkinson WE; Page RL; Connolly SJ;
    J Clin Pharmacol; 2002 Apr; 42(4):388-94. PubMed ID: 11936563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of azimilide, acidemia, and the combination on defibrillation energy requirements.
    Carnes CA; Mehdirad AA
    J Cardiovasc Pharmacol; 2000 Sep; 36(3):283-7. PubMed ID: 10975583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial.
    Pratt CM; Singh SN; Al-Khalidi HR; Brum JM; Holroyde MJ; Marcello SR; Schwartz PJ; Camm AJ;
    J Am Coll Cardiol; 2004 Apr; 43(7):1211-6. PubMed ID: 15063432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.